Lenalidomide

Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 13, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Treatment of Adult T-Cell Leukemia/Lymphoma / Treatment Options for Adult T-Cell Leukemia/Lymphoma / Biological and targeted therapies

In a multicenter phase II study (NCT01724177) of 26 patients with relapsed ATL, the overall response rate was 42% (95% CI, 23%–63%) in patients who received the immunomodulatory agent lenalidomide.[12][Level of evidence C3]

Source links and citations

Studies cited in this source section

Source citation is not a determination that a study applies to you.

NCT01724177 · design, results and side effects

Publication references

Read the original reference and check its publication notices.

PubMed 27621400 · Original source

Preserved source evidence · Independent clinical review pending · Not medical advice